Results 11 to 20 of about 12,515 (211)
Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome. [PDF]
Br J HaematolSummary The role of imatinib in PDGFRA/B‐negative hypereosinophilic syndromes (HES) is controversial because of the heterogeneity of HES and the scarcity of prospective studies. We conducted a phase II clinical trial to evaluate the efficacy of imatinib in PDGFRA/B‐negative HES. Thirty‐two patients were treated with imatinib (100–400 mg daily), and the
Kim DH +15 more
europepmc +2 more sources
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]
Yeungnam University Journal of Medicine, 2019 Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang +2 more
doaj +1 more source
Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience [PDF]
Vojnosanitetski Pregled, 2010 Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).
Ćojbašić Irena +1 more
doaj +1 more source
Imatinib Mesylate for Melanoma: Will a New Target be Revealed? [PDF]
Journal of Investigative Dermatology, 2004 Douglas Grossman
openalex +4 more sources
Do you get the GIST? Successful resection of a giant 3.5 kg gastrointestinal stromal tumour
, 2022 ANZ Journal of Surgery, Volume 92, Issue 12, Page 3356-3359, December 2022.
Luca Borruso +5 more
wiley +1 more source
PLoS ONE, 2014 Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin +7 more
doaj +1 more source
Journal of Medical Case Reports, 2011 Introduction Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors.
Maazaz Khalid +11 more
doaj +1 more source
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018 Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib ...
Eun Hyea Park +3 more
doaj +1 more source
Imatinib mesylate causes hypopigmentation in the skin [PDF]
Cancer, 2003 AbstractBACKGROUNDImatinib mesylate is a tyrosine kinase inhibitor that targets the BCR‐ABL protein in CML, c‐kit (KIT) and platelet‐derived growth factor receptors. In clinical trials with imatinib mesylate, common side effects of nausea, emesis, diarrhea, periorbital edema, fluid retention, and myelosuppression have been documented.METHODSIn this ...
Hagop Kantarjian +4 more
openaire +3 more sources
Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
Iraqi Journal of Hematology, 2020 BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear
Huda A Al-Taee, Azhar K Athab, Ala Ali
doaj +1 more source